To expand Insulin Aspart access in the US

Biocon Biologics announced a collaboration agreement to expand access and affordability of Insulin Aspart in the US. Under the terms of the agreement, Biocon Biologics will supply the Insulin Aspart drug substance to Civica, who will use the drug substance to produce Insulin Aspart drug product, a rapid-acting insulin analogue, at its manufacturing facility in Petersburg, Virginia. Civica will commercialise the medicine for patients in the US, after completion of development work and clinical trials. No technology transfer is involved in the agreement.
 
Shreehas Tambe, CEO and MD, Biocon Biologics said, "Our collaboration with Civica enables us to expand patient access to Insulin Aspart in the United States while reinforcing our dedication to serving the growing needs of people living with diabetes. Together, we are working to ensure more patients have access to high-quality, affordable insulin."
 
Ned McCoy, President and CEO, Civica said, “Civica’s mission is to help people who need access to necessary generic and biosimilar medicines at affordable prices. This includes people living with diabetes, one in five of whom have skipped, delayed, or used less insulin than was needed to save money. Our partnership with Biocon Biologics for Aspart drug substance supply will allow us to deliver on our important mission and help people who need access to Insulin Aspart. Civica will utilise our US-based manufacturing operations in Petersburg, Virginia to produce prefilled pens and vials of insulin.”